John Radford

John Radford

University of Manchester - Manchester / United Kingdom
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 1446807
person_outline John Radford's MOST POPULAR ARTICLES
1-) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphomaML Wang, S Rule, P Martin, A Goy, R Auer, BS Kahl, W Jurczak, ...New England Journal of Medicine 369 (6), 507-516, 201316352013
2-) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II studyB Coiffier, C Haioun, N Ketterer, A Engert, H Tilly, D Ma, P Johnson, ...Blood, The Journal of the American Society of Hematology 92 (6), 1927-1932, 199812531998
3-) Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphomaR Chen, PL Zinzani, MA Fanale, P Armand, NA Johnson, P Brice, ...Journal of Clinical Oncology 35 (19), 2125, 20178732017
4-) Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphomaP Johnson, M Federico, A Kirkwood, A Fosså, L Berkahn, A Carella, ...New England Journal of Medicine 374 (25), 2419-2429, 20168442016
5-) Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphomaJ Radford, T Illidge, N Counsell, B Hancock, R Pettengell, P Johnson, ...New England Journal of Medicine 372 (17), 1598-1607, 20158162015